![]() |
|
|
|
|
|
|
|
![]() |
![]() |
![]() |
|
|
No cardiopulmonary contraindications
No label warnings or precautions regarding patients with:
CONTRAINDICATION PRECAUTIONS ALPHAGAN® P 0.1% has not been studied in patients with hepatic or renal impairment. Caution should be used in treating such patients. ALPHAGAN® P 0.1% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. Patients prescribed IOP-lowering medication should be routinely monitored for IOP. INFORMATION FOR PATIENTS ADVERSE REACTIONS Adverse events occurring in approximately 1% to 4% of the subjects included: allergic reaction, asthenia, blepharitis, blepharoconjunctivitis, blurred vision, bronchitis, cataract, conjunctival edema, conjunctival hemorrhage, conjunctivitis, cough, dizziness, dyspepsia, dyspnea, epiphora, eye discharge, eye dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, fatigue, flu syndrome, follicular conjunctivitis, foreign body sensation, gastrointestinal disorder, headache, hypercholesterolemia, hypotension, infection (primarily colds and respiratory infections), insomnia, keratitis, lid disorder, pharyngitis, photophobia, rash, rhinitis, sinus infection, sinusitis, somnolence, stinging, superficial punctate keratopathy, tearing, visual field defect, vitreous detachment, vitreous disorder, vitreous floaters, and worsened visual acuity. |
|
Indication: ALPHAGAN® P 0.1% ophthalmic solution is indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or Important Safety Information Contraindication: ALPHAGAN® P 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Precautions: Although ALPHAGAN® P 0.1% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. ALPHAGAN® P 0.1% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or Adverse reactions: Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and Please click here for full prescribing information. |



